Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

MEDI507

Known as: MEDI-507 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Antibody-based therapeutic approaches have had a significant impact in the treatment of non-Hodgkin’s lymphoma (NHL). Rituximab’s… Expand
  • table I
  • figure 1
  • table II
Is this relevant?
2009
2009
BACKGROUND Acute graft-versus-host disease (GVHD) is a major complication of both bone marrow and hematologic stem cell… Expand
Is this relevant?
2006
2006
Siplizumab is a humanized monoclonal antibody that selectively binds human CD2 (huCD2), which is expressed on virtually all cells… Expand
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Based on a murine model, we conducted a series of trials of m-myeloablative human leucocyte antigen (HLA)-matched or mismatched… Expand
Is this relevant?
2004
2004
The antihuman CD2 MoAb BTI-322 (Lo-CD2a) effectively inhibits T cell responses in vitro to allogeneic cells, which is followed by… Expand
Is this relevant?
Highly Cited
2003
Highly Cited
2003
We initiated a clinical trial of nonmyeloablative haploidentical stem-cell transplantation (SCT) using MEDI-507, an… Expand
Is this relevant?
2003
2003
Adult T-cell leukemia (ATL) develops in a small proportion of individuals infected with the retrovirus human T-cell leukemia… Expand
Is this relevant?
2003
2003
L'invention concerne l'utilisation d'un antagoniste de CD2, de preference MEDI-507, d'un analogue, d'un derive ou d'un fragment a… Expand
Is this relevant?
1999
1999
CD2 is a 50-kDa transmembrane glycoprotein that plays an important role in T and natural killer (NT) lymphocyte functions. CD2… Expand
Is this relevant?